Drug: Bevacizumab (Avastin, Genentech)
Status: Approved either in combination with carboplatin-paclitaxel or in combination with carboplatin-gemcitabine chemotherapy, followed by bevacizumab alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
Significant Data: Approval is based on results from two randomized controlled, Phase III studies that demonstrated a significant improvement in progression-free survival